Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy

Seminars in Respiratory Infections

Volumn 16, Issue 1, 2001, Pages 60-66

  Clemons, Karl V ^a,b,c   Stevens, David A ^a,b,c  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12;

CELL KILLING; DISEASE SEVERITY; EFFECTOR CELL; GROWTH INHIBITION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE; SYSTEMIC MYCOSIS; T LYMPHOCYTE ACTIVATION;

EID: 0035071902     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2001.22729     Document Type: Review

References (74)

1. Fungal infection in HIV-infected persons
2. Endemic mycoses in AIDS: A clinical review
3. Fungal infections in AIDS patients
4. Endemic mycosis complicating human immunodeficiency virus infection
5. Coccidioidomycosis
6. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity
7. Activation of the complement system by pathogenic fungi
8. Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice
9. Coccidioidomycosis. Part I
10. The epidemiology of blastomycosis
11. Paracoccidioidomycosis: An update
12. Regulation of the immune system by sex steroids
13. The interface of mycology and endocrinology
14. Morphological transition of Paracoccidioides brasiliensis conidia to yeast cells: In vivo inhibition in females
15. Hydrocortisone-enhanced growth of Aspergillus spp.: Implications for pathogenesis
16. Inbred mouse strains differ in resistance to lethal Coccidioides immitis infection
17. Genetic control of resistance to Coccidioides immitis: A single gene that is expressed in spleen cells determines resistance
18. Susceptibility differences of inbred strains of mice to blastomycosis
19. Animal models of systemic mycoses
20. Direct interactions of human natural killer cells with Cryptococcus neoformans inhibit granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha production
21. Modulation of host defenses by cytokines: Evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts
22. Review: Nomenclature and biologic significance of cytokines involved in inflammation and the host immune response
23. Cytokines and mycoses
24. Interleukin 12: A key modulator of immune function
25. Interleukin-10
26. Biologicals and hematopoietic cytokines in prevention or treatment of infections in immunocompromised hosts
27. Colony-stimulating factors and host defense
28. Interferon-gamma and host antimicrobial defense: Current and future clinical applications
29. Protective role of gamma interferon in experimental pulmonary paracoccidioidomycosis
30. Effect of anti-IL-4, interferon-gamma and an antifungal triazole (SCH 42427) in paracoccidioidomycosis: Correlation of IgE levels with outcome
31. A monoclonal antibody to gamma interferon blocks augmentation of natural killer cell activity induced during systemic cryptococcosis
32. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans
33. Interferon gamma increases survival in murine experimental cryptococcosis
34. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice
35. Intrapulmonary response to Histoplasma capsulatum in gamma interferon knockout mice
36. Aspergillus fumigatus conidia induce a Th1-type cytokine response
37. The role of recombinant murine IL-12 and IFN-gamma in the pathogenesis of a murine systemic Candida albicans infection
38. Roles of gamma interferon and interleukin-4 in genetically determined resistance to Coccidioides immitis
39. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis
40. Cytokine treatment of central nervous system infection: Efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis
41. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells
42. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans
43. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice
44. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans
45. Interleukin-12 regulation of host defenses against Coccidioides immitis
46. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma
47. Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum
48. Interleukin-10. Actions and therapeutic potential
49. Immunosuppressive and anti-inflammatory properties of interleukin 10
50. Importance of interleukin-10 in genetic susceptibility of mice to Coccidioides immitis
51. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans
52. Interleukin-4 and -10 exacerbate candidiasis in mice
53. Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococcus neoformans
54. Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection
55. Early resistance of interleukin-10 knockout mice to acute systemic candidiasis
56. Role of IL-10 in invasive aspergillosis: Increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis
57. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis
58. IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus
59. Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: Synergy with fluconazole for killing
60. In vivo and in vitro effects of macrophage colony-stimulating factor (M-CSF) on bronchoalveolar macrophages for antihistoplasmal activity
61. Macrophage colony-stimulating factor (M-CSF) induction of enhanced anticryptococcal activity in human monocyte-derived macrophages: Synergy with fluconazole for killing
62. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus
63. Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens
64. Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration
65. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat
66. The deleterious effect of macrophage colony-stimulating factor (CSF-1) on the pathology of experimental candidiasis in mice
67. Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole
68. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte-colony-stimulating factor and gamma interferon
69. Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Candida infections in normal and immunosuppressed mice
70. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
71. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole
72. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
73. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: An ongoing dilemma or an unnecessary dispute?